리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 06월
페이지 정보:영문 277 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 치료 저항성 우울증 시장은 2030년까지 23억 달러에 도달
2024년에 18억 달러로 추정되는 치료 저항성 우울증 세계 시장은 2024-2030년간 CAGR 3.5%로 성장하여 2030년에는 23억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 항우울제는 CAGR 4.7%를 나타내고, 분석 기간 종료시에는 8억 1,230만 달러에 이를 것으로 예측됩니다. 선택적 세로토닌 재흡수 억제제 부문의 성장률은 분석 기간중 CAGR 2.4%로 추정됩니다.
미국 시장은 5억 340만 달러로 추정, 중국은 CAGR 6.7%로 성장 예측
미국의 치료 저항성 우울증 시장은 2024년에 5억 340만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 4억 5,830만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.7%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.3%와 2.7%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.0%를 보일 전망입니다.
세계의 '치료 저항성 우울증' 시장 - 주요 동향과 촉진요인 정리
치료 저항성 우울증이 전 세계 정신 건강 논의에서 시급히 다뤄져야 하는 이유는 무엇일까?
치료 저항성 우울증(TRD)은 전 세계 정신건강 상황에서 가장 시급하고 복잡한 문제 중 하나로 부상하고 있으며, 최소 두 가지 이상의 표준 항우울제 치료로 충분한 효과를 얻지 못하는 수백만 명에게 영향을 미치고 있습니다. 우울증은 이미 전 세계 신체적 장애의 주요 원인 중 하나이지만, TRD는 만성성, 높은 재발률, 기능 장애, 입원, 자살과의 강한 연관성으로 인해 의료 시스템의 부담을 크게 증가시키고 있습니다. 패러다임의 변화를 가져왔으며, 새로운 진단 기준과 환자 보고 결과를 도입하여 내성 환자를 조기에 발견할 수 있게 되었습니다. 기존 SSRI와 SNRI가 일부 환자에게는 효과가 없습니다는 인식이 확산되면서 새로운 약리학적, 비약리학적 치료법에 대한 수요가 증가하고 있습니다. 정신 건강이 공공 정책의 최전선으로 떠오르면서, 특히 코로나19 팬데믹의 심리적 영향을 고려할 때, TRD는 자금 조달, 기술 혁신, 규제 측면에서 우선적으로 주목받고 있습니다. 환자 옹호, 선별 도구의 개선, 사회적 낙인 제거 캠페인도 TRD를 그늘에서 벗어나게 하고, 그 관리에 대한 보다 적극적이고 다학제적인 접근을 촉진하고 있습니다.
획기적인 치료제는 TRD 치료의 전망을 어떻게 재정의하고 있는가?
TRD 치료 생태계는 기존 모노아민계 항우울제의 한계에 도전하는 새로운 치료제의 승인과 개발로 빠르게 변모하고 있습니다. 이러한 획기적인 신약의 대표적인 것이 케타민에서 파생된 비강용 점비제인 에스케타민입니다. 에스케타민은 여러 시장에서 승인되었으며, TRD 환자에서 신속하고 임상적으로 유의미한 증상 완화를 보여주었습니다. 기존 항우울제와 달리 에스케타민은 글루타메이트계통에 작용하기 때문에 치료가 어려운 것으로 알려진 TRD에 새로운 작용기전을 제공합니다. 환각제 보조요법, 특히 실로시빈과 MDMA를 이용한 치료법도 널리 보급되고 있으며, 임상시험에서 내성이 있는 환자에서도 지속적인 관해를 촉진하는 유망한 결과를 얻었습니다. 이와 함께 경두개자기자극술(TMS), 미주신경자극술(VNS), 뇌심부자극술(DBS)과 같은 신경조절기술은 약물 치료에 반응하지 않는 TRD 환자들을 위한 실행 가능한 대안으로 발전하고 있습니다. 유전자 및 바이오마커 기반 접근법은 임상의가 약물 반응을 예측하고 보다 효과적으로 치료를 조정하는 데 도움을 주고 있습니다. 디지털 치료제와 원격 모니터링 도구도 널리 보급되고 있으며, 인지 행동 지원, 순응도 추적, 실시간 기분 평가 등을 제공함으로써 약물 치료를 강화하고 재발을 줄일 수 있습니다.
TRD의 영향을 가장 많이 받는 의료 시스템과 인구 통계는?
TRD는 고소득 국가의 의료 시스템에 불균형적으로 큰 부담을 초래합니다. 북미와 서유럽에서 TRD는 정신 건강 관련 입원, 장애 청구, 장기 약물 치료 비용의 상당 부분을 차지합니다. 또한, 이들 지역에서는 진단의 정확도가 높고, 첨단 치료법에 대한 접근이 용이하여 새로운 치료법을 빠르게 채택하고 있습니다. 그러나 경제적 어려움, 도시 스트레스, 사회적 고립이 정신 건강 취약성을 악화시키는 동유럽, 라틴아메리카, 아시아태평양 등 중산층을 포함한 전 세계적으로 TRD의 발병률은 증가하고 있습니다. 인구통계학적으로 TRD는 모든 연령대에 영향을 미치지만, 35-60세 성인, 여성, 불안장애 및 당뇨병, 심혈관 질환과 같은 만성 신체질환을 앓고 있는 사람에서 유병률이 높으며, 실업, 외상력, 사회적 지원 부족과 같은 사회적 건강 결정요인이 TRD의 발병과 지속에 중요한 역할을 합니다. 중요한 역할을 하고 있습니다. 인식이 높아짐에 따라 장기적인 부담을 줄이고 치료 저항성을 줄이기 위해 조기 개입, 통합적 치료 모델, 지역사회 기반 정신보건 서비스가 강조되고 있습니다.
치료 저항성 우울증 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.
치료 저항성 우울증 시장은 임상적, 기술적, 사회적 촉진요인의 결합으로 빠르게 성장하고 있습니다. 가장 큰 요인 중 하나는 표준 항우울제에 반응하지 않는 주요우울장애로 진단받은 환자 수가 증가함에 따라 보다 효과적인 대체 약물에 대한 긴급한 수요가 발생하고 있다는 점입니다. 에스케타민과 같은 혁신적인 치료제가 규제 당국의 승인을 받고 환각제 화합물이 임상적으로 성공하면서 새로운 치료 카테고리를 개척하고, 투자를 유치하고, R&D 파이프라인을 가속화하고 있습니다. 이와 함께 뇌 영상, 유전체, AI를 활용한 진단의 발전으로 우울증 하위 유형을 보다 정확하게 분류할 수 있게 되었고, 임상의가 내성이 있는 환자를 보다 빠르고 정확하게 타겟팅할 수 있게 되었습니다. 의료 시스템은 결과의 효과를 중시하는 가치 기반 치료 모델을 채택하고 있으며, TRD에 대한 즉각적이고 지속 가능한 치료법을 사용하도록 인센티브를 제공합니다. 환자 옹호 및 정신의학에 대한 낙인 제거는 환자들이 도움을 요청하고 치료 계획을 준수하도록 장려하고 있으며, 이에 따라 치료 가능한 시장이 확대되고 있습니다. 또한, 신경 조절 및 디지털 치료와 같은 새로운 치료법에 대한 보험 환급이 개선되고 있어 다양한 환자 그룹에 대한 접근성이 향상되고 있습니다. 또한, TRD의 장기적인 경제적 부담(생산성 저하, 신체적 장애, 의료 이용 재발 등)은 정부와 민간 의료 서비스 제공업체에게 이 시장에서의 기술 혁신과 자원 배분의 우선순위를 높이고 있습니다. 그 결과, TRD는 임상적 문제에서 전 세계 정신 건강 관리에 큰 영향을 미치는 성장 분야로 진화하고 있습니다.
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.
Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.
2025년 4월: 협상 단계
이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.
2025년 7월: 최종 관세 재설정
고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.
상호 및 양자 간 무역과 관세의 영향 분석 :
미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국
업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
LSH
영문 목차
영문목차
Global Treatment Resistant Depression Market to Reach US$2.3 Billion by 2030
The global market for Treatment Resistant Depression estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$812.3 Million by the end of the analysis period. Growth in the Selective Serotonin Reuptake Inhibitors segment is estimated at 2.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$503.4 Million While China is Forecast to Grow at 6.7% CAGR
The Treatment Resistant Depression market in the U.S. is estimated at US$503.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$458.3 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.
Why Is Treatment-Resistant Depression Gaining Urgency in Global Mental Health Discussions?
Treatment-resistant depression (TRD) has emerged as one of the most pressing and complex challenges in the global mental health landscape, impacting millions of individuals who fail to respond adequately to at least two standard antidepressant therapies. With depression already among the leading causes of disability worldwide, TRD significantly compounds the burden on healthcare systems due to its chronicity, high relapse rates, and strong association with functional impairment, hospitalization, and suicide. The rising awareness of TRD has led to a paradigm shift in how clinicians assess and stratify depression, incorporating new diagnostic criteria and patient-reported outcomes to identify resistant cases earlier. The growing recognition that conventional SSRIs and SNRIs often prove ineffective for a subset of patients is catalyzing a demand for novel pharmacological and non-pharmacological treatments. As mental health moves to the forefront of public policy-particularly in light of the psychological fallout from the COVID-19 pandemic-TRD is being prioritized for funding, innovation, and regulatory attention. Patient advocacy, better screening tools, and public destigmatization campaigns are also bringing TRD out of the shadows, fostering a more proactive, multidisciplinary approach to its management.
How Are Breakthrough Therapies Redefining the TRD Treatment Landscape?
The TRD treatment ecosystem is undergoing rapid transformation, driven by the approval and development of novel therapeutics that challenge the limitations of traditional monoamine-based antidepressants. Foremost among these breakthroughs is esketamine, a nasal spray derived from ketamine, which has received regulatory approval in multiple markets and demonstrated rapid, clinically significant symptom relief in TRD patients. Unlike conventional antidepressants, esketamine works on the glutamatergic system, offering a new mechanism of action for a notoriously difficult-to-treat condition. Psychedelic-assisted therapies-particularly those involving psilocybin and MDMA-are also gaining ground, with clinical trials showing promising results in promoting sustained remission in otherwise resistant cases. In parallel, neuromodulation techniques such as transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS) are evolving as viable options for TRD patients unresponsive to medication. Personalized medicine is playing a growing role, with genetic and biomarker-based approaches helping clinicians predict drug response and tailor treatments more effectively. Digital therapeutics and remote monitoring tools are also gaining traction, offering cognitive behavioral support, adherence tracking, and real-time mood assessments that can augment pharmacological treatments and reduce relapse.
Which Healthcare Systems and Demographics Are Most Affected by TRD?
TRD poses a disproportionately high burden on healthcare systems in high-income countries, where mental health infrastructure is more robust but also more strained by demand. In North America and Western Europe, TRD accounts for a significant share of mental health-related hospitalizations, disability claims, and long-term pharmacotherapy expenses. These regions also see higher diagnostic accuracy and access to advanced therapies, making them early adopters of new treatment modalities. However, the incidence of TRD is rising globally, including in middle-income regions such as Eastern Europe, Latin America, and parts of Asia-Pacific, where economic hardship, urban stress, and social isolation are exacerbating mental health vulnerabilities. Demographically, TRD affects individuals across age groups but shows elevated prevalence in adults aged 35-60, women, and individuals with comorbid anxiety disorders or chronic physical illnesses such as diabetes and cardiovascular disease. Social determinants of health-such as unemployment, trauma history, and lack of social support-also play a critical role in TRD onset and persistence. As awareness improves, there is growing emphasis on early intervention, integrated care models, and community-based mental health services to reduce the long-term burden and prevent treatment resistance from developing.
The Growth in the Treatment Resistant Depression Market Is Driven by Several Factors…
The treatment-resistant depression market is expanding rapidly due to a confluence of clinical, technological, and societal drivers. One of the foremost factors is the growing patient population diagnosed with major depressive disorder who do not respond to standard antidepressants, creating an urgent need for more effective alternatives. Regulatory approvals of innovative therapies like esketamine and ongoing clinical success of psychedelic compounds are opening new therapeutic categories, attracting investment and accelerating R&D pipelines. In parallel, advances in brain imaging, genomics, and AI-driven diagnostics are enabling more precise stratification of depression subtypes, helping clinicians target resistant cases earlier and more accurately. Healthcare systems are increasingly adopting value-based care models that emphasize outcome efficacy, thereby incentivizing the use of fast-acting and durable treatments for TRD. Patient advocacy and mental health destigmatization are further encouraging individuals to seek help and adhere to treatment plans, enlarging the addressable market. Insurance reimbursement for newer therapies, including neuromodulation and digital therapeutics, is also improving, enhancing access across diverse patient groups. Moreover, the long-term economic burden of TRD-measured in lost productivity, disability, and recurrent healthcare utilization-is pushing governments and private healthcare providers to prioritize innovation and resource allocation in this market. As a result, TRD is evolving from a clinical challenge to a high-impact growth sector in global mental healthcare.
SCOPE OF STUDY:
The report analyzes the Treatment Resistant Depression market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Type (Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents, Other Drug Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 34 Featured) -
AbbVie Inc.
ACADIA Pharmaceuticals
Alkermes plc
AstraZeneca plc
Axsome Therapeutics
Beckley Psytech
Biogen Inc.
Boehringer Ingelheim GmbH
Celon Pharma S.A.
COMPASS Pathways plc
Eli Lilly and Company
GH Research PLC
GlaxoSmithKline plc
H. Lundbeck A/S
Janssen Pharmaceuticals
Navitor Pharmaceuticals
Novartis International AG
Otsuka Pharmaceutical Co., Ltd.
Relmada Therapeutics
SAGE Therapeutics
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Treatment Resistant Depression - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Diagnosis of Mental Health Disorders Expands Treatment Demand
Limitations of Traditional Therapies Propel Demand for Novel Treatments
Rising Awareness and Advocacy Strengthen Business Case for Innovation
Growing Use of Ketamine and Esketamine Spurs Market Growth
Advances in Neurostimulation Therapies Drive Product Development
Digital Mental Health Tools and Telepsychiatry Accelerate Treatment Access
Expanding Pipeline of Novel Antidepressants Generates Hope and Investment
Favorable Reimbursement Policies in Developed Markets Drive Adoption
Genetic and Biomarker Research Strengthens Personalized Treatment Approaches
Stigma Reduction and Workplace Programs Sustain Market Expansion
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Treatment Resistant Depression Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Treatment Resistant Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Selective Serotonin Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Atypical Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Atypical Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Atypical Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: USA 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: USA 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: Canada 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: Canada 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
JAPAN
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: Japan 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: Japan 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
CHINA
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: China 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: China Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: China 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
EUROPE
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Treatment Resistant Depression by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Europe 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Europe 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Europe 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
FRANCE
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: France 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: France Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: France 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
GERMANY
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: Germany 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: Germany 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Italy 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: Italy 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
UNITED KINGDOM
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: UK 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: UK Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: UK 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: Spain 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: Spain 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: Russia 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Russia 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Rest of Europe 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Rest of Europe 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Treatment Resistant Depression by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
AUSTRALIA
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: Australia 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: Australia 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
INDIA
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: India Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 121: India 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: India Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 124: India 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 127: South Korea 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 130: South Korea 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
LATIN AMERICA
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Treatment Resistant Depression by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 139: Latin America 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 142: Latin America 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 145: Latin America 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 148: Argentina 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 151: Argentina 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 154: Brazil 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 157: Brazil 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 160: Mexico 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 163: Mexico 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 166: Rest of Latin America 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 169: Rest of Latin America 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
MIDDLE EAST
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Treatment Resistant Depression by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 172: Middle East 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 175: Middle East 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 178: Middle East 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 181: Iran 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 184: Iran 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 187: Israel 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 190: Israel 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 193: Saudi Arabia 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 196: Saudi Arabia 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 199: UAE 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 202: UAE 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 205: Rest of Middle East 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 208: Rest of Middle East 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
AFRICA
Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 211: Africa 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 214: Africa 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030